JOSH CARLSON, MPH, PhD Senior Post Doctoral Fellow Pharmaceutical Outcomes Research & Policy Program University of Washington Department of Pharmacy Box 357630 Seattle, WA 98195-7630 carlsojj@u.washington.edu Cell: 206.310.0268 Fax: 206.543.3835

RESEARCH INTERESTS:

My current research interests include the economic implications of oncology treatments including the use of diagnostics and pharmacogenomic drug targeting, the strategic use of economic analyses in drug development, and the economic foundations and implications of risk-sharing schemes in the pricing, coverage, and reimbursement of medical products.

WORK EXPERIENCE:

Veritech, Corp., Consultant	10/05 - present
Working with Drs. Veenstra, Sullivan, Ramsey, and Garrison, I prepared deliverables for industry clients including strategic applications to inform drug development as well as formal cost-effectiveness models, budget impact models, and health technology reviews.  Project areas included the use of novel anti cancer agents and diagnostics in the treatment of metastatic colorectal cancer and advanced non-small cell lung cancer.
Genentech, Inc, Intern	6/06 – 9/06
Developed process for linking predictive diagnostic development for Xolair® (omalizumab), an innovative drug used to treat allergic asthma, to commercial goals using economic modeling and analysis.  This health economics and outcomes research position reported directly to the Genentech and joint Genentech and Novartis asthma diagnostic sub teams.
Path, Consultant	1/06 – 5/06
Contracted to perform economic review and analysis of rotavirus vaccine and oral rehydration therapy for prevention and treatment of rotavirus related diarrheal disease.
GeneTests, Research Assistant	7/03 – 9/04
My work at GeneTests focused on the process for inclusion of laboratories conducting pharmacogenetic testing in the GeneTests Lab directory and a project analyzing genetics credentialing for Nurses.
Robert Wood Johnson Foundation, Associate Researcher: Understanding the Human Genome	4/01 – 8/02
This project sought to gather and characterize the diverse perspectives and knowledge levels among key stakeholders confronting issues involving genetic advancement.

EDUCATION:

University of Washington
PhD, Public Health Genetics	2007
MPH, Public Health Genetics	2004
University of Colorado, Boulder
BA, Environmental, Population, Organismic Biology	1997

Dissertation committee:

David L. Veenstra, PharmD, PhD (Chair); veenstra@u.washington.edu

Louis P. Garrison, PhD, lgarrisn@u.washington.edu

Scott D. Ramsey, MD, PhD; sramsey@fhcrc.org

Branko Kopjar, MD, PhD; brankok@u.washington.edu

Research Assistantships:

·        Pharmacogenomics Primer for PhRMA; Principle investigator: Lou Garrison

·        Labcorp Value Project; Principle investigator: Sean Sullivan

·        Genetic Services Policy Project; Principle investigator: Deb Lochner Doyle

• Pharmacogenomic testing of warfarin; Principle investigator: David Veenstra
• Health Policy Analysis Program; Principle investigator: Aaron Katz

Teaching Assistantships: 

• Legal, Ethical, and Social Issues in Public Health Genetics
• Genetics and the Law; Pharmacogenetics and Toxicogenomics
• Pharmacoeconomics, Genetics, and Healthcare.

AWARDS/FELLOWSHIPS:

ISPOR Toronto Best New Investigator Podium Presentation (2008)

Pfizer Inc. Post doctoral fellowship (2007-2009)

PhRMA Foundation Pre Doctoral Fellowship in Health Outcomes Research (2007)

PUBLICATIONS

Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer. Value Health. Jul 18 2008.

Carlson JJ, Veenstra DL, Ramsey SD. Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs. 2008;68(8):1105-1113.

Garrison LP, Jr., Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM, Veenstra DL. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metab Rev. 2008;40(2):377-401.

Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer. Sep 2008;61(3):405-415.

Garrison LP, Veenstra DL, Carlson RJ, Carlson JJ, Meckley LM. Backgrounder on Pharmacogenomics for the Pharmaceutical and Biotechnology Industries: Basic Science, Future Scenarios, Policy Directions – Final Report. Seattle: University of Washington; 2007.

Ramsey SD, Veenstra DL, Garrison LP, Jr., Carlson, RJ, Billings, P, Carlson, JJ, Sullivan, SD. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. Am J Manag Care. Apr 2006;12(4):197-202.

Carlson JJ, Henrikson N. B., Veenstra D. L., Ramsey S. D. Economic analyses of human genetics services: A systematic review. Genetics in Medicine. 2005;7(8):519-523.

Billings PR, Carlson RJ, Carlson JJ, et al. Ready for genomic medicine? Perspectives of health care decision makers. Arch Intern Med. Sep 12 2005;165(16):1917-1919.

Carlson JJ, Carlson RJ. The Cost of Progress Canadian Healthcare Manager. 2003;10(3).

Meeting Abstracts and Podium Presentations:

Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. Economic evaluation of EGFR-guided treatment in advanced refractory non small-cell lung cancer. Paper presented at: ISPOR 13th Annual International Meeting, 2008; Toronto, CA.

Carlson JJ, Oestreicher N, Lubeck DP, Ramsey SD, Veenstra DL. Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2007;25:7664.

Carlson JJ, Beidler-Henrikson N, Veenstra DL, Ramsey SD. Economic Analyses of Human Genetics Services: A Systematic Review. Paper presented at: Investing in Health: iHEA 5th World Congress, 2005; Barcelona, Spain

Carlson JJ. Genetics Credentials in Nursing Practice. Paper presented at: NCHPEG/GROW Seventh annual meeting, 2004; Bethesda, MD.

OTHER

Finisher, Portland Marathon, Oct. 2003